AHL
HRTX icon

Abel Hall LLC’s Heron Therapeutics HRTX Stock Holding History

Abel Hall LLC’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91K Buy
213,185
+196,278
+1,161% +$157K 0.02% 850
2026
Q1 		$13.5K Sell
16,907
-29,269
-63% -$33.9K ﹤0.01% 798
2025
Q4 		$60K Buy
+46,176
New +$57K 0.01% 643

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Abel Hall LLC's HRTX Position: Q2 2026 in Review

Abel Hall LLC increased its Heron Therapeutics (HRTX) stake by 1,161% in Q2 2026, buying an estimated $157K and bringing the position to 213,185 shares worth $91K. The position accounts for 0.02% of the portfolio, ranked #850.

Abel Hall LLC first reported a position in HRTX in Q4 2025 and has held it in 3 quarters since. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Abel Hall LLC held 213,185 shares of Heron Therapeutics worth $91K as of Q2 2026.
  • Abel Hall LLC bought 196,278 Heron Therapeutics shares in Q2 2026, an estimated $157K.
  • Heron Therapeutics made up 0.02% of Abel Hall LLC's portfolio in Q2 2026, its #850 holding.
  • Abel Hall LLC first reported a position in Heron Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.